drugset / Trial / NCT04405960

Role of Alphacalcidol Supplement to Reduce Pain and COMP in Geriatric Knee Osteoarthritis Patients

NCT04405960

RandomizedParallel-groupTriple-blindTreatment

Summary

Indonesian population's life expectancy has been increasing steadily in the last 3 decades. It potentially increases the prevalence of degenerative diseases, including osteoarthritis (OA). Serum Vitamin D (25(OH)D) level has been recognized as a risk factors for knee OA. Cartilage Oligomeric Matrix Protein (COMP) is cartilage degradation product can be used as a diagnostic marker for knee OA. This study aims to determine the effect of Vitamin D supplementation (Alphacalcidol) on pain based on WOMAC indicators and joint cartilage condition based on COMP serum markers in knee OA elderly patients.

Timeline

Start
2017-07-01
Primary completion
2017-09-30
Completion
2017-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Alfacalcidol Other / unclassified 1 ug Oral

Indications